Search

Displaying results 7691 - 7700 of 10000 in total
  1. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (Aβ), [L50978] which is found in the brain amyloid plaques that … [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.

    Synonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS APP (AMYLOID BETA A4 PRECURSOR PROTEIN) A BETA 3-PYROGLUTAMYL PEPTIDES, A.BETA. 3 (3-X)), HUMANIZED MONOCLONAL ANTIBODYGAMMA1 HEAVY CHAIN HUMANIZED (1-444) (, Immunoglobulin G1, anti-(human pyroglutamyl Aβ (3-x) peptide)(human clone LY3002813 γ1-chain), disulfide with human clone LY3002813 κ-chain, dimer
  2. Drug

    Ordesekimab

    go.drugbank.com/drugs/DB16649
    Investigational

    Ordesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease).

  3. Drug

    Avotaciclib

    go.drugbank.com/drugs/DB16652
    Investigational

    Avotaciclib is under investigation in clinical trial NCT03579836 (Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient With Pancreatic Cancer).

    Synonyms: 2,6-bis(2-aminopyrimidin-4-yl)pyridin-3-ol
  4. Drug

    Orticumab

    go.drugbank.com/drugs/DB16653
    Investigational

    Orticumab is under investigation in clinical trial NCT04776629 (A Proof-of-activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors).

  5. Drug

    Zotiraciclib

    go.drugbank.com/drugs/DB16656
    Investigational

    Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide

  6. Drug

    Bentracimab

    go.drugbank.com/drugs/DB16659
    Investigational

    Bentracimab is under investigation in clinical trial NCT04286438 (Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-threatening Bleeding or Requiring Urgent Surgery or

    Categories: Heterocyclic Compounds, 2-Ring
  7. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414] … Endogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h.

  8. Drug

    Oxelumab

    go.drugbank.com/drugs/DB16663
    Investigational

    Oxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).

  9. Drug

    Bucelipase alfa

    go.drugbank.com/drugs/DB16664
    Investigational

    Bucelipase alfa is under investigation in clinical trial NCT00743483 (Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency).

  10. Drug

    Pimivalimab

    go.drugbank.com/drugs/DB16667
    Investigational

    Pimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After